Nature Medicine: COMPASS Pan-Cancer Model Predicts Immunotherapy Response
marinkazitnik · x · 2026-07-03
A Harvard Medical School team published a paper in Nature Medicine introducing COMPASS, a pan-cancer foundation model that predicts immune checkpoint inhibitor responses by analyzing tumor transcriptomes. While about a quarter of advanced cancer patients derive lasting benefits from immunotherapy, existing tools (like TMB and PD-L1 staining) lack reliability across different cancer types. COMPASS not only predicts durable responses across various cancers but also uncovers the specific biological mechanisms behind each prediction, holding the potential to significantly improve precision in immunotherapy selection for advanced cancer patients.
More from Research
- Stanford's PaperFormalizer turns research papers into Lean-verified versions with author in the loop — StanfordUniversity · 2026-10-27
- JockeyBench uses Japanese horse racing to test LLM agents — all betting strategies lose money — Zhongwei Xie · 2026-10-27
- Cohere's Invent-A-Dataset paper: zero-seed synthetic data beats frontier APIs on quality and diversity — idanbeck · 2026-10-27
- Hugging Face TRL makes score centering + masked importance sampling default in async GRPO — _lewtun · 2026-10-27
- AutoResearch agent's weird training curve gets dug into instead of discarded — ZimingLiu11 · 2026-10-27
- EMNLP 2026: sub-billion-parameter LMs show superhuman entity tracking, human-like fleeting memory — GretaTuckute · 2026-10-27